- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT04310371
Exposure to CARDIovascular Risk Assessed by Cardiac Adiposity in oBese adOlescents Eligible to a Residential Long-term Lifestyle Intervention by Diet and eXercise (CARDIBOX) (CARDIBOX)
Exposure to CARDIovascular Risk Assessed by Cardiac Adiposity in oBese adOlescents Eligible to a Residential Long-term Lifestyle Intervention by Diet and eXercise
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
The investigators aim to improve knowledge of the association between epicardial adipose tissue, myocardial lipid content, and left ventricular regional myocardial function.
In this protocol, obese adolescents are recruited undergoing a 3-month lifestyle intervention residential program. Adolescents from the intervention group will be enrolled at the obesity center for the whole school year. The obesity center employs a multidisciplinary team to provide the best weight management care to adolescents during their stay. The weight loss program is an integral part of the obesity center program and fundamentally combines physical activity with a normocaloric diet monitored by a dietician. The physical activity program consists of two training sessions (aerobic and resistance training) per week. Moreover, adolescents will be engaged in two additional sessions per week, consisting in recreational activities such as ball and racquet games, trekking, snowshoeing or swimming.
There will be two measurement time: one at baseline (Day 0) and one at three months after the beginning of the lifestyle intervention (M3). The controls will be evaluated at baseline only.
Statistical analysis will be performed using Stata software (version 13; Stata-Corp, College Station, Tex., USA). All statistical tests will be two-sided and p inferior to 0.05 will be considered significant. Qualitative variables will be described in terms of numbers and proportions. Quantitative variables will be described in terms of numbers, mean standard deviation or median according to statistical distribution (normality studied using Shapiro-Wilk test). Graphic representations will be complete presentations of results. The main analysis will be performed with the Stata software (version 13, StataCorp, College Station). All statistical tests will be carried out at a risk of error of first species α set at 5%. Most of the analysis of the secondary evaluation criteria will be exploratory in nature and may lack power in terms of numbers. As discussed by Feise in 2002,104 the adjustment of the risk of error of 1st species will not be systematically proposed, but case by case in view of clinical considerations and not only statistical (e.g. Sidak correction for the analysis of correlation coefficients).
Qualitative variables will be described in terms of numbers and proportions. Quantitative variables will be described in terms of standard deviation or mean median according to statistical distribution (normality studied using Shapiro-Wilk test). Graphic representations will be complete presentations of results.
Intergroup comparisons will be systematically conducted without adjustment and by adjusting for factors whose distribution could be unbalanced between groups. Patients will be described and compared between groups at inclusion according to the following variables: compliance with eligibility criteria, epidemiological characteristics, clinical characteristics and characteristics of possible treatments. The baseline comparability of the two groups will be assessed on the main characteristics of the participants and potential factors associated with the primary outcome. A possible difference between the two groups on one of these characteristics will be determined according to clinical considerations and not solely statistical ones.
Tipo di studio
Iscrizione (Anticipato)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
-
Clermont-Ferrand, Francia, 63000
- CHU de Clermont-Ferrand
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- age between 12 and 16 years old
- mature (menarche)
- suitable for physical activity
- able to give an informative consent
- affiliated at French insurance company
- consent from the legal representatives
- For obese adolescents: BMI greater than the 97th percentile of national curves.
- For the control group: to be normal-weighted (no obesity if overweight, <85th percentile of national curves).
Exclusion Criteria:
- Medical or surgical history judged by the investigator as incompatible with the study
- Drugs that may interfere with the study results
- Cardiovascular, hepatic, psychiatric, renal, or endocrinological diseases
- Smoking
- Alcohol consumption
- Intense physical activity in competition
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Obese adolescents
BMI greater than the 97th percentile of national curves.
Participants will follow a 3-month lifestyle intervention
|
Adolescents from the intervention group will be enrolled at the obesity center for the whole school year (i.e., 10 months). The physical activity program consists of two training sessions (aerobic and resistance training) per week. There will be two measurement time: one at baseline (Day 0) and one at three months after the beginning of the lifestyle intervention (M3). The controls will be evaluated at baseline only. |
|
Nessun intervento: Control group
to be normal-weighted (no obesity if overweight, <85th percentile of national curves).
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
cardiac ectopic fat deposits
Lasso di tempo: Month 3
|
Quantification of cardiac ectopic fat deposits (thickness using echocardiography)
|
Month 3
|
|
cardiac ectopic fat deposits
Lasso di tempo: Day 0
|
Quantification of cardiac ectopic fat deposits (thickness using echocardiography)
|
Day 0
|
|
cardiac ectopic fat deposits
Lasso di tempo: Day 0
|
Quantification of cardiac ectopic fat deposits (volume using MRI)
|
Day 0
|
|
cardiac ectopic fat deposits
Lasso di tempo: Month 3
|
Quantification of cardiac ectopic fat deposits (volume using MRI)
|
Month 3
|
|
cardiac ectopic fat deposits
Lasso di tempo: Month 3
|
Quantification of cardiac ectopic fat deposits (myocardial triglyceride content evaluated by MRI)
|
Month 3
|
|
cardiac ectopic fat deposits
Lasso di tempo: Day 0
|
Quantification of cardiac ectopic fat deposits (myocardial triglyceride content evaluated by MRI)
|
Day 0
|
|
left myocardial regional function
Lasso di tempo: Month 3
|
left myocardial regional function (echocardiography)
|
Month 3
|
|
left myocardial regional function
Lasso di tempo: Month 3
|
left myocardial regional function (MRI)
|
Month 3
|
|
left myocardial regional function
Lasso di tempo: Day 0
|
left myocardial regional function (echocardiography)
|
Day 0
|
|
left myocardial regional function
Lasso di tempo: Day 0
|
left myocardial regional function (MRI)
|
Day 0
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
macrovascularisation
Lasso di tempo: Day 0
|
measure of carotid intima-media thickness (CIMT) using High-resolution B-mode ultrasound
|
Day 0
|
|
macrovascularisation
Lasso di tempo: Month 3
|
measure of carotid intima-media thickness (CIMT) using High-resolution B-mode ultrasound
|
Month 3
|
|
microvascularisation
Lasso di tempo: Month 3
|
measure of blood flow velocity using laser speckle contrast imaging (LSCI)
|
Month 3
|
|
microvascularisation
Lasso di tempo: Day 0
|
measure of blood flow velocity using laser speckle contrast imaging (LSCI)
|
Day 0
|
|
microvascularisation
Lasso di tempo: Day 0
|
measure of microvascular perfusion using laser-Doppler flowmetry (LDF)
|
Day 0
|
|
microvascularisation
Lasso di tempo: Month 3
|
measure of microvascular perfusion using laser-Doppler flowmetry (LDF)
|
Month 3
|
|
microvascularisation
Lasso di tempo: Month 3
|
measure of microvascular perfusion using Iontophoresis procedure
|
Month 3
|
|
microvascularisation
Lasso di tempo: Day 0
|
measure of microvascular perfusion using Iontophoresis procedure
|
Day 0
|
|
microvascularisation
Lasso di tempo: Day 0
|
measure of microvascular perfusion using flowmotion
|
Day 0
|
|
microvascularisation
Lasso di tempo: Month 3
|
measure of microvascular perfusion using flowmotion
|
Month 3
|
|
heart rate variability
Lasso di tempo: Month 3
|
measure of heart rate variability using a holter
|
Month 3
|
|
heart rate variability
Lasso di tempo: Day 0
|
measure of heart rate variability using a holter
|
Day 0
|
|
skin conductance
Lasso di tempo: Day 0
|
measure of skin conductance using Wristband electrodes - Empatica E4
|
Day 0
|
|
skin conductance
Lasso di tempo: Month 3
|
measure of skin conductance using Wristband electrodes - Empatica E4
|
Month 3
|
|
Liver steatosis
Lasso di tempo: Month 3
|
measure of liver steatosis by MRI
|
Month 3
|
|
Liver steatosis
Lasso di tempo: Day 0
|
measure of liver steatosis by MRI
|
Day 0
|
|
Liver steatosis
Lasso di tempo: Day 0
|
measure of liver steatosis by fibroscanner (ultrasonic attenuation)
|
Day 0
|
|
Liver steatosis
Lasso di tempo: Month 3
|
measure of liver steatosis by fibroscanner (ultrasonic attenuation)
|
Month 3
|
|
Liver steatosis
Lasso di tempo: month 3
|
measure of liver steatosis by Aixplorer (Lipersonic Imagine®)
|
month 3
|
|
Liver steatosis
Lasso di tempo: Day 0
|
measure of liver steatosis by Aixplorer (Lipersonic Imagine®)
|
Day 0
|
|
Liver fibrosis
Lasso di tempo: Day 0
|
measure of liver fibrosis by fibroscanner (liver stiffness)
|
Day 0
|
|
Liver fibrosis
Lasso di tempo: Month 3
|
measure of liver fibrosis by fibroscanner (liver stiffness)
|
Month 3
|
|
Liver fibrosis
Lasso di tempo: Month 3
|
measure of liver fibrosis by fibrotest (Lipersonic Imagine®)
|
Month 3
|
|
Liver fibrosis
Lasso di tempo: Day 0
|
measure of liver fibrosis by fibrotest (Lipersonic Imagine®)
|
Day 0
|
|
blood pressure
Lasso di tempo: Day0
|
measure of blood pressure using sphygmomanometer
|
Day0
|
|
blood pressure
Lasso di tempo: month 3
|
measure of blood pressure using sphygmomanometer
|
month 3
|
|
Fitness
Lasso di tempo: Month 3
|
6-minutes walking test to assess functional capacity at a sub-maximal level, and the effects of exercise training in cardiac and pulmonary patients.
|
Month 3
|
|
Fitness
Lasso di tempo: Day 0
|
6-minutes walking test to assess functional capacity at a sub-maximal level, and the effects of exercise training in cardiac and pulmonary patients.
|
Day 0
|
|
muscle mass
Lasso di tempo: Month 3
|
measure of muscle mass using impedancemeter
|
Month 3
|
|
fat mass
Lasso di tempo: Month 3
|
measure of muscle mass using impedancemeter
|
Month 3
|
|
bone structure
Lasso di tempo: Month 3
|
measure of muscle mass using impedancemeter
|
Month 3
|
|
muscle mass
Lasso di tempo: Day 0
|
measure of muscle mass using impedancemeter
|
Day 0
|
|
fat mass
Lasso di tempo: Day 0
|
measure of muscle mass using impedancemeter
|
Day 0
|
|
bone structure
Lasso di tempo: Day 0
|
measure of muscle mass using impedancemeter
|
Day 0
|
|
muscle mass
Lasso di tempo: Day 0
|
measure of muscle mass using Densitometry X-ray absorption
|
Day 0
|
|
fat mass
Lasso di tempo: Day 0
|
measure of muscle mass using Densitometry X-ray absorption
|
Day 0
|
|
bone structure
Lasso di tempo: Day 0
|
measure of muscle mass using Densitometry X-ray absorption
|
Day 0
|
|
muscle mass
Lasso di tempo: Month 3
|
measure of muscle mass using Densitometry X-ray absorption
|
Month 3
|
|
fat mass
Lasso di tempo: Month 3
|
measure of muscle mass using Densitometry X-ray absorption
|
Month 3
|
|
bone structure
Lasso di tempo: Month 3
|
measure of muscle mass using Densitometry X-ray absorption
|
Month 3
|
|
muscle mass
Lasso di tempo: Month 3
|
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
|
Month 3
|
|
fat mass
Lasso di tempo: Month 3
|
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
|
Month 3
|
|
bone structure
Lasso di tempo: Month 3
|
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
|
Month 3
|
|
muscle mass
Lasso di tempo: Day 0
|
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
|
Day 0
|
|
fat mass
Lasso di tempo: Day 0
|
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
|
Day 0
|
|
bone structure
Lasso di tempo: Day 0
|
measure of muscle mass using Peripheral quantitative computed tomography (pQCT)
|
Day 0
|
|
muscle mass
Lasso di tempo: Day 0
|
measure of muscle mass using Quantitative ultrasounds (QUS)
|
Day 0
|
|
fat mass
Lasso di tempo: Day 0
|
measure of muscle mass using Quantitative ultrasounds (QUS)
|
Day 0
|
|
bone structure
Lasso di tempo: Day 0
|
measure of muscle mass using Quantitative ultrasounds (QUS)
|
Day 0
|
|
muscle mass
Lasso di tempo: Month 3
|
measure of muscle mass using Quantitative ultrasounds (QUS)
|
Month 3
|
|
fat mass
Lasso di tempo: Month 3
|
measure of muscle mass using Quantitative ultrasounds (QUS)
|
Month 3
|
|
bone structure
Lasso di tempo: Month 3
|
measure of muscle mass using Quantitative ultrasounds (QUS)
|
Month 3
|
|
depression
Lasso di tempo: Day 0
|
depression is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always".
|
Day 0
|
|
depression
Lasso di tempo: Month 3
|
depression is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always".
|
Month 3
|
|
anxiety
Lasso di tempo: Day 0
|
anxiety is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always".
It is also evaluated by the State-Trait Anxiety Inventory (STAI) composed by two dimensions, state anxiety and trait anxiety, both evaluated with a 20-items questionnaire on a 4-point scale from "never" to "always"
|
Day 0
|
|
anxiety
Lasso di tempo: Month 3
|
anxiety is assessed by the Hospital Anxiety and Depression scale (HAD) composed by 7 items and a 4-point scale from "never" to "always".
It is also evaluated by the State-Trait Anxiety Inventory (STAI) composed by two dimensions, state anxiety and trait anxiety, both evaluated with a 20-items questionnaire on a 4-point scale from "never" to "always"
|
Month 3
|
|
General health
Lasso di tempo: Day 0
|
general health is assessed by the short form 36 health survey (SF36) composed by 36 items
|
Day 0
|
|
General health
Lasso di tempo: Month 3
|
general health is assessed by the short form 36 health survey (SF36) composed by 36 items
|
Month 3
|
|
Stress
Lasso di tempo: day 0
|
stress is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
|
day 0
|
|
Stress
Lasso di tempo: Month 3
|
stress is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
|
Month 3
|
|
Fatigue
Lasso di tempo: Day 0
|
Fatigue is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
|
Day 0
|
|
Fatigue
Lasso di tempo: Month 3
|
Fatigue is assessed by a Visuel analog scale of 100mm ranging from very low (0) to very high (100)
|
Month 3
|
|
Sleep
Lasso di tempo: day 0
|
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
|
day 0
|
|
Sleep
Lasso di tempo: Month 3
|
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
|
Month 3
|
|
Burnout
Lasso di tempo: day 0
|
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
|
day 0
|
|
Burnout
Lasso di tempo: Month 3
|
Burnout is assessed by the Maslach Burn-out Inventory (MBI) composed by 22 items and a 7-point scale ranging from "never" to "every day".
|
Month 3
|
|
Mindfulness
Lasso di tempo: Day 0
|
Midfuless is assessed by the Freiburg Mindfulness Inventory-14 (FMI) composed by a 4-point Likert scale ranging from 1 (strongly disagree) to 4 (strongly agree)
|
Day 0
|
|
Mindfulness
Lasso di tempo: Month 3
|
Midfuless is assessed by the Freiburg Mindfulness Inventory-14 (FMI) composed by a 4-point Likert scale ranging from 1 (strongly disagree) to 4 (strongly agree)
|
Month 3
|
|
Coping
Lasso di tempo: Day 0
|
Coping is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by an 11-point scale
|
Day 0
|
|
Coping
Lasso di tempo: Month 3
|
Coping is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by an 11-point scale
|
Month 3
|
|
Emotions
Lasso di tempo: Day 0
|
Emotions are assessed by the Emotion Régulation Questionnaire (ERQ) composed by 10 items on a 7-point likert scale ranging from 1 (strongly disagree) to 7 (strongly agree)
|
Day 0
|
|
Emotions
Lasso di tempo: Month 3
|
Emotions are assessed by the Emotion Régulation Questionnaire (ERQ) composed by 10 items on a 7-point likert scale ranging from 1 (strongly disagree) to 7 (strongly agree)
|
Month 3
|
|
Perception of work
Lasso di tempo: Day 0
|
Work perception is assessed by the Job Demand-Control-Support (JDSC) questionnaire of Karasek composed by 26 items on a 4-point scale ranging from 1 (strongly disagree) to 4 (strongly agree).
It is also evaluated by the effort-reward imbalance model (ERI) of Siegrist composed by 46 items on a 5-point scale ranging from 1 (no agreement) to 5 (agree and very disturb).
|
Day 0
|
|
Perception of work
Lasso di tempo: Month 3
|
Work perception is assessed by the Job Demand-Control-Support (JDSC) questionnaire of Karasek composed by 26 items on a 4-point scale ranging from 1 (strongly disagree) to 4 (strongly agree).
It is also evaluated by the effort-reward imbalance model (ERI) of Siegrist composed by 46 items on a 5-point scale ranging from 1 (no agreement) to 5 (agree and very disturb).
|
Month 3
|
|
Self-efficacy
Lasso di tempo: Day 0
|
Self-efficacy is assessed by the perceived self-efficacy scale composed by 10 items on a 4-point scale
|
Day 0
|
|
Self-efficacy
Lasso di tempo: Month 3
|
Self-efficacy is assessed by the perceived self-efficacy scale composed by 10 items on a 4-point scale
|
Month 3
|
|
Alexithymia
Lasso di tempo: Day 0
|
Alexithymia is assessed by the Twenty-item Toronto Alexithymia Scale (TAS20) composed by a 5-point scale from "strongly agree" to "strongly disagree".
|
Day 0
|
|
Alexithymia
Lasso di tempo: Month 3
|
Alexithymia is assessed by the Twenty-item Toronto Alexithymia Scale (TAS20) composed by a 5-point scale from "strongly agree" to "strongly disagree".
|
Month 3
|
|
Illness perception
Lasso di tempo: Day 0
|
Perception of illness is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by a 11-point scale.
|
Day 0
|
|
Illness perception
Lasso di tempo: Month 3
|
Perception of illness is assessed by the Brief Illness Perception Questionnaire (B-IPQ) composed by a 11-point scale.
|
Month 3
|
|
Metacognition
Lasso di tempo: Day 0
|
Metacognition is assessed by the MetaCognition Questionnaire (MCQ-30) composed by 30 items on a 5-point scale
|
Day 0
|
|
Metacognition
Lasso di tempo: Month 3
|
Metacognition is assessed by the MetaCognition Questionnaire (MCQ-30) composed by 30 items on a 5-point scale
|
Month 3
|
|
Time perception
Lasso di tempo: Day 0
|
Perception of the time is assessed by the Metacognitive questionnaire on time perception (MQT) composed by 24 items on a 5-point scale.
It is also evaluated by the Zimbardo Time Perspective Inventory (ZPTI) composed by 56 items on a 5-point scale from "very uncharacteristic" to "very characteristic".
|
Day 0
|
|
Time perception
Lasso di tempo: Month 3
|
Perception of the time is assessed by the Metacognitive questionnaire on time perception (MQT) composed by 24 items on a 5-point scale.
It is also evaluated by the Zimbardo Time Perspective Inventory (ZPTI) composed by 56 items on a 5-point scale from "very uncharacteristic" to "very characteristic".
|
Month 3
|
|
Physical activity
Lasso di tempo: Day 0
|
Physical activity is assessed by the Recent Physical Activity Questionnaire (RPAQ)
|
Day 0
|
|
Physical activity
Lasso di tempo: Month 3
|
Physical activity is assessed by the Recent Physical Activity Questionnaire (RPAQ)
|
Month 3
|
|
Life style
Lasso di tempo: Day 0
|
life style is assessed with a questionnaire on coffee consumption, food intake, etc
|
Day 0
|
|
Life style
Lasso di tempo: Month 3
|
life style is assessed with a questionnaire on coffee consumption, food intake, etc
|
Month 3
|
|
cholesterol
Lasso di tempo: Day 0
|
measure by blood analyses to evaluate alloplastic load
|
Day 0
|
|
triglycerides
Lasso di tempo: Day 0
|
measure by blood analyses to evaluate alloplastic load
|
Day 0
|
|
cholesterol
Lasso di tempo: Month 3
|
measure by blood analyses to evaluate alloplastic load
|
Month 3
|
|
triglycerides
Lasso di tempo: Month 3
|
measure by blood analyses to evaluate alloplastic load
|
Month 3
|
|
Cortisol
Lasso di tempo: Day 0
|
hormone measure by blood analyses to evaluate alloplastic load
|
Day 0
|
|
Cortisol
Lasso di tempo: Month 3
|
hormone measure by blood analyses to evaluate alloplastic load
|
Month 3
|
|
DHEAS
Lasso di tempo: day 0
|
hormone measure by blood analyses to evaluate alloplastic load
|
day 0
|
|
DHEAS
Lasso di tempo: Month 3
|
hormone measure by blood analyses to evaluate alloplastic load
|
Month 3
|
|
BDNF
Lasso di tempo: Day 0
|
proteins measure by blood analyses to evaluate alloplastic load
|
Day 0
|
|
BDNF
Lasso di tempo: Month 3
|
proteins measure by blood analyses to evaluate alloplastic load
|
Month 3
|
|
CRP
Lasso di tempo: Day 0
|
proteins measure by blood analyses to evaluate alloplastic load
|
Day 0
|
|
pro-inflammatory cytokines
Lasso di tempo: Day 0
|
proteins measure by blood analyses to evaluate alloplastic load
|
Day 0
|
|
TNF alpha
Lasso di tempo: Day 0
|
proteins measure by blood analyses to evaluate alloplastic load
|
Day 0
|
|
CRP
Lasso di tempo: Month 3
|
proteins measure by blood analyses to evaluate alloplastic load
|
Month 3
|
|
pro-inflammatory cytokines
Lasso di tempo: Month 3
|
proteins measure by blood analyses to evaluate alloplastic load
|
Month 3
|
|
TNF alpha
Lasso di tempo: Month 3
|
proteins measure by blood analyses to evaluate alloplastic load
|
Month 3
|
|
NPY
Lasso di tempo: Month 3
|
proteins measure by blood analyses to evaluate alloplastic load
|
Month 3
|
|
NPY
Lasso di tempo: Day 0
|
proteins measure by blood analyses to evaluate alloplastic load
|
Day 0
|
|
Leptin
Lasso di tempo: Day 0
|
measure by blood analyses to evaluate appetite regulation
|
Day 0
|
|
Leptin
Lasso di tempo: Month 3
|
measure by blood analyses to evaluate appetite regulation
|
Month 3
|
|
Ghrelin
Lasso di tempo: Day 0
|
measure by blood analyses to evaluate appetite regulation
|
Day 0
|
|
Ghrelin
Lasso di tempo: Month 3
|
measure by blood analyses to evaluate appetite regulation
|
Month 3
|
|
NPY
Lasso di tempo: day 0
|
measure by blood analyses to evaluate appetite regulation
|
day 0
|
|
NPY
Lasso di tempo: Month 3
|
measure by blood analyses to evaluate appetite regulation
|
Month 3
|
|
adiponectine
Lasso di tempo: Day 0
|
measure by blood analyses to evaluate appetite regulation
|
Day 0
|
|
adiponectine
Lasso di tempo: Month 3
|
measure by blood analyses to evaluate appetite regulation
|
Month 3
|
|
CCK
Lasso di tempo: Day 0
|
measure by blood analyses to evaluate appetite regulation
|
Day 0
|
|
Month 3
Lasso di tempo: Day 0
|
measure by blood analyses to evaluate appetite regulation
|
Day 0
|
|
Insulin
Lasso di tempo: Day 0
|
measure by blood analyses to evaluate glucid metabolism
|
Day 0
|
|
Insulin
Lasso di tempo: Month 3
|
measure by blood analyses to evaluate glucid metabolism
|
Month 3
|
|
HbA1c
Lasso di tempo: Day 0
|
measure by blood analyses to evaluate glucid metabolism
|
Day 0
|
|
HbA1c
Lasso di tempo: Month 3
|
measure by blood analyses to evaluate glucid metabolism
|
Month 3
|
|
glucose
Lasso di tempo: Day 0
|
measure by blood analyses to evaluate glucid metabolism
|
Day 0
|
|
glucose
Lasso di tempo: Month 3
|
measure by blood analyses to evaluate glucid metabolism
|
Month 3
|
|
Albumin
Lasso di tempo: Day 0
|
measure by blood analyses to evaluate protid metabolism
|
Day 0
|
|
Albumin
Lasso di tempo: Month 3
|
measure by blood analyses to evaluate protid metabolism
|
Month 3
|
|
transthyretin
Lasso di tempo: Day 0
|
measure by blood analyses to evaluate protid metabolism
|
Day 0
|
|
transthyretin
Lasso di tempo: Month 3
|
measure by blood analyses to evaluate protid metabolism
|
Month 3
|
|
Homeostasis
Lasso di tempo: Day 0
|
measure of Fibroblast growth factor 23 (FGF23) by blood analyses to evaluate bone metabolism
|
Day 0
|
|
Homeostasis
Lasso di tempo: Month 3
|
measure of Fibroblast growth factor 23 (FGF23) by blood analyses to evaluate bone metabolism
|
Month 3
|
|
Osteoresorption
Lasso di tempo: Day 0
|
measure of C-terminal Telopeptide of Type I collagen (CTx) by blood analyses to evaluate bone metabolism
|
Day 0
|
|
Osteoresorption
Lasso di tempo: Month 3
|
measure of C-terminal Telopeptide of Type I collagen (CTx) by blood analyses to evaluate bone metabolism
|
Month 3
|
|
Osteoformation
Lasso di tempo: Day 0
|
measure of decarboxylated osteocalcine and BSAP by blood analyses to evaluate bone metabolism
|
Day 0
|
|
Osteoformation
Lasso di tempo: Month 3
|
measure of decarboxylated osteocalcine and BSAP by blood analyses to evaluate bone metabolism
|
Month 3
|
|
VEGF
Lasso di tempo: Day 0
|
measure by blood analyses to evaluate cardiovascular function
|
Day 0
|
|
VEGF
Lasso di tempo: Month 3
|
measure by blood analyses to evaluate cardiovascular function
|
Month 3
|
|
PAI1
Lasso di tempo: Day 0
|
measure by blood analyses to evaluate cardiovascular function
|
Day 0
|
|
PAI1
Lasso di tempo: Month 3
|
measure by blood analyses to evaluate cardiovascular function
|
Month 3
|
|
weight
Lasso di tempo: Day 0
|
measure of weight in kilograms
|
Day 0
|
|
weight
Lasso di tempo: Month 3
|
measure of weight in kilograms
|
Month 3
|
|
waist circumference
Lasso di tempo: Day 0
|
measure of waist circumference in centimetres
|
Day 0
|
|
waist circumference
Lasso di tempo: Month 3
|
measure of waist circumference in centimetres
|
Month 3
|
Collaboratori e investigatori
Collaboratori
Studiare le date dei record
Studia le date principali
Inizio studio (Anticipato)
Completamento primario (Anticipato)
Completamento dello studio (Anticipato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- RBHP 2019 DUTHEIL
- 2019-A01804-53 (Altro identificatore: ANSM)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .